Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (366)	6/3/2008 8:17:55 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 566

Folicular...... several patients at stable disease, appear to be resolving long-term into formal responses..... 8 of 11 patients demo'd clinical benefit. PR requires at least 50% reduction in lymph node size, took several months for a PR to evolve to CR. Some of the PRs have been "rather durable". Have seen patients who have remained on drug for nearly a year with no significant toxicities. Published toxicity results with revlimid indicate more problems with low blood counts than with 788. Subset of patients of subset that were not heavily pre-treated had a transient INCREASE in blood counts. Seeking a global partner who can handle indications for both autoimmunity and oncology.